

# Aging Issues in People with Intellectual Disabilities

**Dr. Kerry Boyd, MD.**  
**Psychiatrist**  
**Chief Clinical Officer**  
**Bethesda**

**Assistant Clinical Professor**  
**Department of**  
**Psychiatry and Behavioural Neurosciences**  
**McMaster University**



# Overview

**I. DUAL DIAGNOSIS**

**II. AGING ISSUES**

**III. PARTICULAR PATHOLOGIES**

**a) Medical**

**b) Medication-Related**

**c) Mental Health**

**d) Special Mention: Down Syndrome**

**IV. CARE CONSIDERATIONS**

A photograph of a sunset over the ocean. The sun is a bright yellow-orange orb in the center of the sky, which transitions from a deep orange near the horizon to a lighter, hazy orange at the top. The horizon line is dark, and the water below is a deep, dark blue-black. A small, dark silhouette of a lighthouse is visible on the horizon to the left. The entire image is framed by a thin, light-colored border.

*The longer the shoreline of knowledge  
the greater the sea of mystery.*

**Author Unknown**

# LEARNING OBJECTIVES

- **Appreciate multiple factors affecting the well being of aging individuals who have an I.D.**
- **Consider the impact (for better or for worse) of psychotropic medications in the elderly.**
- **Outline an approach to treatment.**
- **Review observations regarding aging and dementia in the Down Syndrome population.**

# I. DUAL DIAGNOSIS

= Intellectual disability and mental health problem

- “10%-70%” of those with I.D.
- Higher incidence of mental health problems than general population
- May be challenging to identify the underlying problem(s)
- Can be effectively managed
- Requires comprehensive assessment and a BIO/PSYCHO/SOCIAL approach
- Unlike other countries (e.g. UK) few formal specialist training opportunities

## II. AGING ISSUES

- **Lifespan is longer (on average)**
- **Aging is inevitable**
- **Loss and change are unavoidable**
- **Reactions are variable**
- **Factors to consider:**
  - **Medical/Physical**
  - **Neurological**
  - **Sensory**
  - **Cognitive**
  - **Psychiatric**
  - **Syndrome-specific aging issues (e.g. D.S.)**

# AGING ISSUES, CONT'D.

- **Problems may be multiple, even synergistic, contributing to distress or dysfunction**
- **Certain treatments may compound the problems**
- **Interference with development, relationships, quality of life**

# **III. PARTICULAR PATHOLOGIES**

**a) Medical**

**b) Medication-Induced**

**c) Mental Health**

**d) Special Mention: Down Syndrome**



## **a) Medical Issues of Aging**

- **Increased incidence**
- **Atypical presentations**
- **Proactive prevention**
- **Head to toe review of systems**
- **Increased surveillance and screening**
- **NB comorbidities**

## **b) Medication-Related Problems**

- **Always in the differential diagnosis or on the “suspect list”**
- **Look for this especially in aging individuals**
- **High incidence of psychotropic drug Rx and polypharmacy**
- **Long-term use – tardive side effects, tolerance, withdrawal**



## **b) Medication-Related Problems**

- **In those with I.D., aging may be associated with increased drug levels, interactions, or sensitivity**
- **In those with Dual Diagnosis there are particular cautions**

## **b) Medication-Related Problems**

### **Psychotropic Drug Side Effects**

- **Neuroleptics:**
  - **High Potency (e.g. haloperidol) → extra pyramidal side effects (EPS), Parkinsonism, akathisia, acute dystonias and tardive dyskinesia**
  - **Low Potency (e.g. chlorpromazine) → some EPS, anticholinergic effects (constipation, urinary retention ...), pseudo dementia, EKG/cardiac effects, pigmentary retinopathy, sedation, weight gain**

## **b) Medication-Related Problems**

### **Psychotropic Drug Side Effects, Cont'd.**

- **Newer neuroleptics (e.g. Risperidone, Olanzapine):**
  - **EPS at higher doses – increased sensitivity in elderly**
  - **Sedation**
  - **Weight gain, obesity, diabetes, dyslipidemias**
  - **Risk for cardiac and cerebrovascular disease**

## **b) Medication-Related Problems**

- **Benzodiazepines:**
  - **Sedation, ataxia, dysinhibition**
- **Antidepressants**
  - **Variable effects and side effects**
  - **Consider akathisia**

## **b) Medication-Related Problems**

### **Psychotropic Drug Side Effects, Cont'd.**

- **Mood-Stabilizers**
  - **Lithium** → lower doses in older individuals
  - **Anticonvulsants** → monitor
- **NB side effects of side effect medications (e.g. Cogentin → anticholinergic)**

## **c) Mental Health**

- **“The human condition”**
- **Medical and mental (psychiatric) disorders may present atypically**
- **Be a sleuth! (team sleuthing)**
- **Consider B.E.A.M.S.**



## **c) Mental Health**

- **Mental health problems are common in the elderly with I.D.**
- **Psychiatric diagnoses 20%-40% depending on survey and definition of “elderly”**
- **Same problems as with dual diagnosis in younger population**

## **c) Mental Health**

- **“Behaviour problems” less prevalent especially in those with mild impairment**
- **Affective disorders and dementia more prevalent**
- **Other disorders unchanged**
- **NB context & stressors: loss, grief, residential relocation**
- **Importance of pre-planning**

**Adapted from Psychiatric Problems in Older Persons with Developmental Disabilities. Ed. Robert Pary. NADD press, 2002**

# Dementia in the I.D. Population

- **Prevalence is higher than in the general population**
- **Similarities in presentation (clinical features, progression, pathology)**
- **R/O physical or mental health and medication-related problems**
- **NB frequent/severe physical and sensory comorbidities which influence social and adaptive functioning**
- **Also NB dementia risk factors (Hypertension, ↑ lipids, obesity, diabetes, Down Syndrome)**

## **d) Special Mention: Down Syndrome**

- **Increased longevity**
- **Many living into 50's and 60's**
- **Early aging (premature greying, hair loss, skin, and adipose changes, cataracts, hypogonadism)**
- **Increased autoimmune disorders, malignancies, vascular disease, and diabetes**

# Dementia in Down Syndrome

- **1948 clinical presentation of Alzheimer's Disease in D.S. described**
- **Trisomy 21 → 3 copies of Beta-Amyloid or Amyloid Precursor Protein (APP) gene which is linked to A.D.**
- **Autopsy → neuronal loss, senile plaques (containing beta amyloid peptide), neurofibrillary tangles**
- **This same pathology is seen in brains 30-40 years including those who died without clinical A.D.**
- **Some evidence the process begins in childhood.**

# Dementia in Persons with D.S.

- **Ages 40 – 49**                      **10% - 25%**
- 50 – 59**                      **28% - 55%**
- 60 – 69**                      **30% - 75%**

Vandyke, Harper, Dykens  
Down Syndrome and A.D., 1998

# How is Diagnosis Established?

- **Exclude medical conditions that can mimic Dementia (hypothyroidism, hypercalcemia, depression, vitamin deficiencies, medication effects, sensory/physical impairment, etc.)**
- **Demonstrate decline from previous level of functioning (importance of baseline history and testing)**
- **DSM IV definition of Dementia of the Alzheimer's type = the development of multiple cognitive deficits include: memory and at least one of aphasia, apraxia, agnoria, disturbance of executive function.**
- **Decline is progressive (multiple assessments)**

# Bethesda Outreach Services

- Noted ↑ in referrals to psychology department for assessment of cognitive decline from 1990-2000 especially D.S. → query dementia
- 14% of referrals for cognitive decline were for ⊕ dementia
- 20% inconclusive; 3% “other”
- Of the 62% that were ⊖ for dementia, health status, environmental changes and adjustment difficulties were explored



# IV. CARE CONSIDERATIONS

- **Management principles**
  - **BIO/PSYCHO/SOCIAL teamwork**
  - **Manage the manageable**
  - **Treat specific disorders specifically**
  - **Start low, go slow**
  - **Monitor response – effects and side effects**
  - **Review**
  - **Revise as indicated**

Adapted from many wise clinicians

# CARE CONSIDERATIONS

## Recommendations for caregivers:

**C**ommunication enhance! hearing aids, connect with memories ...

**A**ssessment stages of dementia, contributing factors ...

**R**espect ↑ understanding/ ↓ frustration ...

**E**nvironment modifications, visual cues, supports, assists ...

From Paul J. Patti, presentation: Overview of Aging and Dementia in Older Individuals with Developmental Disabilities, George A. Jervis Clinic, Institute for Basic Research in Developmental Disabilities, Staten Island, New York



# Resources

- Alzheimer Society of Canada [www.alzheimer.ca](http://www.alzheimer.ca)
- Canadian Down Syndrome Society [www.cdss.ca](http://www.cdss.ca)
- National Down Syndrome Society <http://www.ndss.org>
- Down Syndrome Quarterly [www.denison.edu/dsq/](http://www.denison.edu/dsq/)
- Down Syndrome Health Care Guidelines
- Down Syndrome Quarterly, 1999 [http://www.ds-health.com/record sheet 1 htm](http://www.ds-health.com/record_sheet_1.htm)

# Resources, Cont'd.

- **Health Care Management of Adults with Down Syndrome, Dr. David S. Smith, American Family Physician Sept. 2001, [www.aafp.org/aft](http://www.aafp.org/aft)**
- **Developmental Disabilities Resources for Health Care Providers [www.dd healthinfo.org/](http://www.ddhealthinfo.org/)**
- **Evidence-Based Mental Health (linking research to practice) [www.ebmentalhealth.com](http://www.ebmentalhealth.com)**

# Resources, Cont'd.

- **Dual Diagnosis: An Introduction to the Mental Health Needs of Persons with Developmental Disabilities Ed. Griffiths, Stavonbaks, Summers, 2002, CHAPTER 16 – Aging and Dual Diagnosis, Fidler & McCCasey**
- **Psychiatric Problems in Older Persons with Developmental Disabilities. Ed. R. Pary NADD press, 2002**
- **Dementia, Aging, and Intellectual Disabilities, a handbook, ed. M. Janicki, A. Dalton**

# Resources Cont'd

- [www.opadd.on.ca](http://www.opadd.on.ca)
- [www.rgpc.ca](http://www.rgpc.ca)
- [www.alzheimerniagara.ca](http://www.alzheimerniagara.ca)
- [www.ontgerontology.on.ca](http://www.ontgerontology.on.ca)
- [www.citizenship.gov.on.ca/seniors](http://www.citizenship.gov.on.ca/seniors)